HIMS Stock Analysis: Buy, Sell, or Hold?
HIMS - Hims & Hers Health, Inc.
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Aug 24, 2026 at $31.02 · last confirmed Aug 24, 2026
Get Alerted When HIMS Hits Your Target Price
Join 10,000+ traders who never miss a move
Interactive Price Chart (1 Month)
Loading historical data...
âšī¸ NEUTRAL: HIMS is fairly priced but lacks strong directional signals. At 10.1% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Technical Outlook: Technically, HIMS is in a uptrend. Immediate support is located at $27.38, while resistance sits at $34.46. The stock is showing strong short-term momentum, up 6.1% recently.
Market Sentiment: HIMS scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Protect Your Profits
Holding HIMS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.1%)
- NEUTRAL: Near Wall St target ($31.23)
- BULLISH: Expecting earnings turnaround to 10.1% growth with 38.2% revenue growth
- WARNING: Composite score 39/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
Support & Resistance Levels
Fundamental Context
Data refreshes hourly during market hours. Next update: 11:02 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Is HIMS showing a specific setup today?
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$212 | 77 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 54 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$101 | 51 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 68 BUY |
|
UTHR
United Therapeutics CorpâĻ |
STRONG BUY
15 analysts |
$664 | 52 HOLD |
Advanced HIMS Option Strategies
Professional options setups generated by AI based on today's HIMS price and gamma walls.
